Efficacy and safety of lixilan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial
Investigations into Metabolic Pathways Some murine studies suggest that AOD 9604 may encourage lipolytic processes in adipose tissues
Key Takeaways BioCare shows up for GLP-1 patients beyond the product
Report to the Joint Budget Committee, House Health, Insurance, and Environment Committee, House Public Health Care and Human Services Committee, and Senate Health and Human Services Committee on Medicaid Payment Reform and Innovation Pilot Program. April 15, 2017
Compounded medications may involve additional considerations compared to FDA-approved products, but in certain clinical circumstances, they may offer alternative formulation or dosing options when deemed appropriate by a prescribing provider